Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4733961 | 0.76 | CYP2A6 (0.38) | CA1CA2 | |
| SCHEMBL4731836 | 0.76 | ALOX15 (0.38) | CA1CA2 | |
| SCHEMBL11224081 | 0.70 | LMNA (0.33) | — | |
| SCHEMBL874303 | 0.70 | — | — | |
| SCHEMBL13719990 | 0.70 | — | — | |
| SCHEMBL3984911 | 0.70 | KMT2A (0.36) | CA1CA2 | |
| SCHEMBL76934 | 0.70 | MEN1 (0.36) | CA1CA2 | |
| SCHEMBL1946653 | 0.70 | KMT2A (0.38) | — | |
| SCHEMBL76560 | 0.68 | LMNA (0.32) | — | |
| SCHEMBL7074888 | 0.68 | ALDH1A1 (0.39) | CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723020-B2 | Use of azetidinone compounds | SCHERING CORPORATION (US) | 2010-05-25 | — | — | US | disclosed |
| US-20070105141-A1 | Use of azetidinone compounds | SCHERING CORPORATION (US) | 2007-05-10 | — | — | US | disclosed |
| US-7144696-B2 | Use of azetidinone compounds | SCHERING CORPORATION (US) | 2006-12-05 | — | — | US | disclosed |
| US-20050208568-A1 | Use of azetidinone compounds | SCHERING CORP. | 2005-09-22 | — | — | US | disclosed |
| US-6933107-B2 | Use of azetidinone compounds | SCHERING CORPORATION (US) | 2005-08-23 | — | — | US | disclosed |
| US-20030215869-A1 | Use of azetidinone compounds | ALTMANN SCOTT W (US) | 2003-11-20 | — | — | US | disclosed |
| US-6632933-B2 | Use of azetidinone compounds | SCHERING CORPORATION | 2003-10-14 | — | — | US | disclosed |
| US-6593078-B1 | Identifying a protein that mediates cholesterol absorption by using DNA expression library; incubating cells with a fluorescent cholesterol absorption inhibitor; use in treating atherosclerotic coronary heart disease | SCHERING CORPORATION | 2003-07-15 | — | — | US | disclosed |
| US-20020009714-A1 | Use of azetidinone compounds | ALTMANN SCOTT W (US) | 2002-01-24 | — | — | US | disclosed |
| WO-2000063703-A1 | USE OF AZETIDINONE COMPOUNDS | SCHERING CORPORATION (US) | 2000-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030215869-A1 | Use of azetidinone compounds | NPC1L1, NPC1, CYP46A1 | CA1 4792/4885CA2 4461/4885 |
| US-20070105141-A1 | Use of azetidinone compounds | NPC1L1, NPC1, CYP46A1 | CA1 4799/4885CA2 4475/4885 |
| US-20050208568-A1 | Use of azetidinone compounds | NPC1L1, NPC1, CYP46A1 | CA1 4792/4885CA2 4461/4885 |
| US-20020009714-A1 | Use of azetidinone compounds | NPC1L1, NPC1, CYP46A1 | CA1 4792/4885CA2 4461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.